Results 11,121-11,140 of 12,718 for speaker:Louise O'Reilly

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: A broad range of questions have been asked. I ask witnesses to do their best to answer. The asking of questions in batches is not ideal but it is the procedure of the committee. I ask witnesses to try to answer all questions posed.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Could Mr. Hennessy explain the difference between the two different assessments and how IPHA's figure is different from the HSE's?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Senator Burke wants to come back in at this point.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: The Senator has made that point. Can we resume going back through the questions and then the Senator will have an opportunity-----

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Okay, that is fair.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Very briefly, Senator Mullen. Other people are also trying to get in.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I am going to ask Senator Mullen to hold his questions for now because other members have indicated and I know they are under time pressure.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I did not say that.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: A point was raised about reimbursement and figures that I got in response to a parliamentary question indicate that there are nine drugs that have cleared the hurdle and await approval of some form from the Health Service Executive, HSE. That ties in with many of the questions being asked this morning. People who watch this process closely do not do it for fun. They do it because they have...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I ask Mr. Hennessy to be very specific and not vague. When he says that we will require additional resourcing, is he saying that, as we sit here, the money is not available to fund these, so those people who are waiting for those nine drugs may as well forget waiting, because there is no point and that is not going to happen? Is it going to happen? Saying that there is a funding issue is...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Presumably they have passed the clinical effectiveness tests at this point.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: The clinical effectiveness test is not an issue. The issue then is the €120 million over five years.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: And that is all that it is?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Does Mr. Hennessy have any indication of whether it in the HSE's plans, budgets or is any movement going to be made in this regard, or will those nine drugs simply sit waiting? When Mr. Hennessy talks about effectiveness, outcomes and such, all of those hurdles have been cleared and now we find ourselves with nine drugs sitting somewhere in some sort of funding-related limbo which they may...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: There is a large number of questions that the witnesses have to get through, and we will make sure that they are answered. I am conscious that there is another group of three, and one more Deputy indicating. We will go back to the questions. I ask the witnesses to focus on very specific answers.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I ask the Deputy to hold his questions until we have a rota in operation.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I do not believe that there is anything in legislation that precludes Mr. Hennessy from answering the specific question that was asked.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: A specific drug was referred to, so, verbal gymnastics aside, I do not know how Mr. Hennessy is going to be able to answer the question without addressing the drug. It was Deputy Kelly's question and related to a specific drug.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: The answer to that question is that this drug is cost effective, then.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I was surmising that part of the answer to the question is that the drug is cost effective. We can tick that box, that it is cost effective.